Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients

Globally, colorectal cancer (CRC) ranks as one of the most prevalent types of cancers at the moment, being the second cause of cancer-related deaths. The CRC chemotherapy backbone is represented by 5-fluorouracil, oxaliplatin, irinotecan, and their combinations, but their administration presents sev...

Full description

Saved in:
Bibliographic Details
Published in:Materials 2021-05, Vol.14 (9), p.2440
Main Authors: Ginghină, Octav, Hudiță, Ariana, Zaharia, Cătălin, Tsatsakis, Aristidis, Mezhuev, Yaroslav, Costache, Marieta, Gălățeanu, Bianca
Format: Article
Language:English
Subjects:
Bioavailability
Cancer
Cancer therapies
Chemotherapy
Colorectal cancer
Current carriers
Cytotoxicity
Drug delivery systems
Drug therapy
Growth factors
Medical prognosis
Metastasis
Mortality
Nanoparticles
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Globally, colorectal cancer (CRC) ranks as one of the most prevalent types of cancers at the moment, being the second cause of cancer-related deaths. The CRC chemotherapy backbone is represented by 5-fluorouracil, oxaliplatin, irinotecan, and their combinations, but their administration presents several serious disadvantages, such as poor bioavailability, lack of tumor specificity, and susceptibility to multidrug resistance. To address these limitations, nanomedicine has arisen as a powerful tool to improve current chemotherapy since nanosized carriers hold great promise in improving the stability and solubility of the drug payload and enhancing the active concentration of the drug that reaches the tumor tissue, increasing, therefore, the safety and efficacy of the treatment. In this context, the present review offers an overview of the most recent advances in the development of nanosized drug-delivery systems as smart therapeutic tools in CRC management and highlights the emerging need for improving the existing in vitro cancer models to reduce animal testing and increase the success of nanomedicine in clinical trials.
ISSN:1996-1944
1996-1944
DOI:10.3390/ma14092440